#USA #Palo Alto #oncology #SageMedic #SAGE Oncotest

SageMedic Corp Establishes Business Advisory Board

In a pioneering move towards enhancing functional precision oncology, SageMedic Corp (SAGE) has announced the formation of its Business Advisory Board. This strategic initiative aims to complement the existing Scientific and Medical Advisory Board, creating a robust framework that integrates both business and medical insights.

Goals of the Advisory Board

The cornerstone of the newly formed board is the early adoption of the SAGE Oncotest™, a unique functional precision oncology platform. The platform is specifically designed to identify optimal treatment plans for patients battling cancer. By amalgamating expert business strategies with scientific insights, SageMedic intends to empower oncologists, enabling them to make well-informed, individualized treatment decisions based on the latest innovations in oncology.

Dr. Christian Apfel, President and CEO of SageMedic, expressed his enthusiasm about the formation of this board, stating, "We are honored to have such distinguished experts join our Business Advisory Board. With their guidance, SAGE is poised to expand its reach in functional precision oncology, helping oncologists make more informed, individualized treatment decisions."

Meet the Experts on the Board

The Business Advisory Board consists of several prominent figures from various sectors, each offering unique insights and guidance:

• - Archelle Georgiou, MD - A physician and former Chief Medical Officer at United Health Group, Dr. Georgiou draws on her comprehensive experience to support the development of patient-centered business strategies at SageMedic.
• - Scott Minick, MBA - Minick brings a wealth of knowledge from his background as a former Managing Director at Arch Venture Partners, assisting SageMedic with scaling biotech innovations and strategic investments.
• - Mika Newton - Currently the CEO of xCures, Newton specializes in establishing collaborations within AI-driven precision medicine, thereby enhancing SageMedic’s growth through data-informed commercial partnerships.
• - Michael Seiden, MD, PhD - With a background as former CEO of Fox Chase Cancer Center and Chief Medical Officer at McKesson, Dr. Seiden's extensive clinical and leadership experience guides SageMedic through the complexities of healthcare systems.
• - Jeffrey Venstrom, MD - As the previous SVP of Medical Affairs at GRAIL, Dr. Venstrom provides invaluable insights on advancing precision medicine initiatives and navigating regulatory environments within oncology networks.

Innovative Solutions in Oncology

SageMedic Corp is revolutionizing cancer treatment through its SAGE Oncotest™ platform, which utilizes an AI-augmented, in-vitro, live 3D microtumor model. This cutting-edge technology significantly outstrips the capabilities of conventional genomic testing, delivering precise and actionable insights. The aim is to enable oncologists to tailor treatment plans that are profoundly personalized, ensuring that every patient receives care tailored to their unique tumor biology.

The vision behind the SAGE Oncotest™ is ambitious yet clear: enhance the likelihood of tumor response, improve patient quality of life, and extend overall survival rates—all while potentially lowering healthcare costs. This initiative exemplifies SageMedic's commitment to transforming oncology, ensuring that patients receive the best possible care based on the latest scientific advancements.

Conclusion

SageMedic Corp's establishment of its Business Advisory Board marks a significant step in its journey towards empowering oncologists with the tools they need to deliver personalized treatment. As the fight against cancer continues, this strategic move will not only bolster the company’s initiatives but also position it as a leader in the functional precision oncology market.